Cited by 146Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Lin, Chia-Chi, Shih, Jin-Yuan, Yu, Chong-Jen, Ho, Chao-Chi, Liao, Wei-Yu, Lee, Jih-Hsing, Tsai, Tzu-Hsiu, Su, Kang-Yi, Hsieh, Min-Shu, Chang, Yih-Leong, Bai, Ya-Ying, Huang, Derek De-Rui, Thress, Kenneth S, Yang, James Chih-Hsin·2018·The Lancet Respiratory Medicine

DOI 10.1016/s2213-2600(17)30480-0

Open this paper in CoChat — free account

Abstract

Background Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs.Methods Eligible patients had been enrolled at one centre in the AURA study, had shown resistance to a previous EGFR TKI, and had EGFR-activating mutations and acquired Thr790Met mutation detectable in tumour tissue or plasma. Patients took 20-240 mg osimertinib per day until disease progression or development of intolerable side-effects. Plasma samples were collected every 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression. We tested samples for resistance mechanisms, including EGFR-activating, Thr790Met, and Cys797Ser mutations, and assessed associations with overall survival, progression-free survival, and survival after disease progression.Findings Of 71 patients enrolled in AURA, 53 were eligible for this analysis. Median progression-free survival was 11·1 months (95% CI 8·4-13·9) and overall survival was 16·9 months (11·7-29·1). 47 patients had disease progression. Median overall survival after osimertinib progression was 5·4 months (95% CI 4·1-10·0). Plasma samples were available for 40 patients after disease progression. 12 (30%) of these had the Thr790Met mutation (four of whom also had Cys797Ser mutations). Patients without detectable EGFR-activating mutations in plasma before treatment had the best overall and post-progression survival (22·4 months, 95% CI 15·6-not reached, and 10·8 months, 7·2-not reached, respectively). Loss of the Thr790Met mutation but presence of EGFR-activating mutations in plasma were associated with the shortest progression-free survival (median 2·6 months, 95% CI 1·3-not reached). In 22 post-progression tumour samples, we found one squamous cell and two small-cell transformations. We detected Thr790Met in nine (50%) of 18 samples, Cys797Ser in two (17%) of 12, cMET amplification in five (50%) of ten, BRAF mutation in one (8%) of 13, and KRAS mutation in one (8%) of 13.Interpretation Heterogeneous resistance mechanisms developed in patients receiving osimertinib. Differences in resistance mechanisms might dictate future development strategies for osimertinib in clinical trials.Funding AstraZeneca, Taiwan Ministry of Science and Technology.

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(17)30480-0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citation
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Self-citation
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
Self-citation
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 563
Self-citation

Show all 23 references

Sorted by citations

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,448
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 432
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 417
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC
Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387
Self-citation
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
He, J., Huang, Z., Han, L., Gong, Y. Q., & Xie, C. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5270 · Cited by 339
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Chmielecki, J., Gray, J. E., Cheng, Y., Ohe, Y., Imamura, F., Cho, B. C., Lin, M., Majem, M., Shah, R. N. H., Rukazenkov, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35961-y · Cited by 298
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Wang, Q., Yang, S., Wang, K., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0759-9 · Cited by 267
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Gelatti, A., Drilon, A. E. D. C., & Santini, F. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.017 · Cited by 220
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Chmielecki, J., Mok, T. S. K., Wu, Y.-L. L. C., Han, J., Ahn, M., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C., Shepherd, F. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35962-x · Cited by 214
Self-citation
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 202
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Schrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 146
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
Gomatou, G., Syrigos, N. K., & Kotteas, E. A. (2023) · Cancers · doi:10.3390/cancers15030841 · Cited by 137
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
Li, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., Yang, S., Zhu, L., Guo, S., Zhao, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01082-8 · Cited by 120
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2021) · Cancers · doi:10.3390/cancers13194926 · Cited by 107
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 103
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
Mehlman, C., Cadranel, J. L., Rousseau-Bussac, G., Lacave, R., Pujals, A., Girard, N., Callens, C., Gounant, V., Théou–Anton, N., Friard, S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.019 · Cited by 98
Acquired resistance mechanisms to osimertinib: The constant battle
Zalaquett, Z., Hachem, M. C. R., Kassis, Y., Hachem, S., Eid, R., Kourié, H. R., & Planchard, D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102557 · Cited by 100
The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments
Capua, D. D., Bracken-Clarke, D. M., Ronan, K. E., Baird, A., & Finn, S. P. (2021) · Cancers · doi:10.3390/cancers13163923 · Cited by 98
Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer
Hsu, C., Liao, B.-C., Liao, W., Markovets, A. A., Stetson, D., Thress, K. S., & Yang, J. C. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.006 · Cited by 86
Self-citation
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Udagawa, H., Hasako, S., Ohashi, A., Fujioka, R., Hakozaki, Y., Shibuya, M., Abe, N., Komori, T., Haruma, T., Terasaka, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0419 · Cited by 76
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Zhu, V. W., Klempner, S. J., & Ou, S. I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.008 · Cited by 73
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Sun, R., Hou, Z., Zhang, Y., & Jiang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13528 · Cited by 77
Liquid Biopsy to Identify Actionable Genomic Alterations
Ou, S. I., Nagasaka, M., & Zhu, V. W. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199765 · Cited by 71
Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
Abate, R. E., Frezzetti, D., Maiello, M. R., Gallo, M., Camerlingo, R., Luca, A. D., Cecio, R. D., Morabito, A., & Normanno, N. (2020) · Cancers · doi:10.3390/cancers12123804 · Cited by 69
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Herbreteau, G., Vallée, A., Charpentier, S., Normanno, N., Hofman, P. M., & Denis, M. G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.18 · Cited by 65
Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
Hayashi, H., Nadal, E., Gray, J. E., Ardizzoni, A., Caria, N., Puri, T., & Grohé, C. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.009 · Cited by 63
IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer
Manabe, T., Yasuda, H., Terai, H., Kagiwada, H., Hamamoto, J., Ebisudani, T., Kobayashi, K., Masuzawa, K., Ikemura, S., Kawada, I., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0956 · Cited by 60
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 63
INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance
Smit, E. F., Dooms, C., Raskin, J., Nadal, E., Tho, L. M., Le, X., Mazières, J., Hin, H. S., Morise, M., Zhu, V. W., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-1406 · Cited by 56
Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
Seto, T., Nogami, N., Yamamoto, N., Atagi, S., Tashiro, N., Yoshimura, Y., Yabuki, Y., & Saka, H. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0064-8 · Cited by 56
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
Bordi, P., Re, M. D., Minari, R., Rofi, E., Buti, S., Restante, G., Squadrilli, A., Crucitta, S., Casartelli, C., Gnetti, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.017 · Cited by 52
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Li, X., Chen, C., Wang, Z., Liu, J., Sun, W., Shen, K., Lv, Y., Zhu, S., Zhan, P., Lv, T., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02075-8 · Cited by 52
Genomics of adult and pediatric solid tumors.
Rahal, Z., Abdulhai, F., Kadara, H. N., & Saab, R. H. (2018) · Europe PMC (PubMed Central) · Cited by 52
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 52
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
Wang, Y., Tian, P., Xia, L., Li, L., Han, R., Zhu, M., Lizaso, A., Tian, Q., Li, M., Yu, B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.003 · Cited by 48
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
Bertoli, E., Carlo, E. D., Conte, A. D., Stanzione, B., Revelant, A., Fassetta, K., Spina, M., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136936 · Cited by 48
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Shah, M. P., & Neal, J. W. (2022) · Drugs · doi:10.1007/s40265-022-01698-z · Cited by 47
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
Zhang, Y., Chen, Z., Zhang, X., Xu, C., Yan, H., Xie, Z., Chuai, S., Ye, J., Han‐Zhang, H., Zhang, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.030 · Cited by 45
Self-citation
Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer
Lee, J., Kim, H. S., Lee, B., Kim, H. K., Sun, J., Ahn, J. S., Ahn, M., Park, K., & Lee, S. (2020) · Cancer · doi:10.1002/cncr.32809 · Cited by 46
Self-citation
Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
Cai, X., Jing, M., Sun, R., Wang, S., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Rosell, R., & Cao, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105701 · Cited by 41
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Zhao, S., Li, X., Zhao, C., Jiang, T., Jia, Y., Shi, J., He, Y., Li, J., Zhou, F., Gao, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.010 · Cited by 40
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
Filipska, M., & Rosell, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12983 · Cited by 38
Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction
Vadla, G. P., Daghat, B., Patterson, N., Ahmad, V., Perez, G., Garcia, A., Manjunath, Y., Kaifi, J. T., Li, G., & Chabu, C. Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-10598-x · Cited by 38
Cutting-Edge Therapies for Lung Cancer
La’ah, A. S., & Chiou, S. (2024) · Cells · doi:10.3390/cells13050436 · Cited by 36
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Michels, S. Y. F., Heydt, C., van Veggel, B. A. M. H., Deschler-Baier, B., Pardo, N., Monkhorst, K., Rüsseler, V., Stratmann, J., Griesinger, F., Steinhauser, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00210 · Cited by 36
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
Gray, J. E., Markovets, A. A., Reungwetwattana, T., Majem, M., Nogami, N., Peled, N., Lee, J. S., Cho, B. C., Chewaskulyong, B., John, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.07.008 · Cited by 33
Self-citation
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
Nakamura, T., Nakashima, C., Komiya, K., Kitera, K., Hirai, M., Kimura, S. H., & Sueoka‐Aragane, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209384 · Cited by 33
TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
Liang, L., He, H., Jiang, S., Liu, Y., Huang, J., Sun, X., Li, Y., Jiang, Y., & Li, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810415 · Cited by 31
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 32
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
Uchibori, K., Inase, N., Nishio, M., Fujita, N., & Katayama, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.005 · Cited by 32
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28
Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
Oh, D. K., Ji, W., Kim, W. S., Choi, C., Yoon, S., Rho, J. K., & Lee, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210225 · Cited by 28
Self-citation
Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors
Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., et al. (2019) · Cancer · doi:10.1002/cncr.32481 · Cited by 28
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Raphael, A., Dudnik, E., Hershkovitz, D., Jain, S., Olsen, S., Soussan‐Gutman, L., Ben-Shitrit, T., Dvir, A., Nechushtan, H., Peled, N., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092475 · Cited by 27
Histologic transformation in lung cancer: when one door shuts, another opens
Sato, Y., Saito, G., & Fujimoto, D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221130503 · Cited by 27
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
Hsu, P., Lee, S.-H., Chiu, L., Lee, C.-S., Wu, C., Kuo, C. S., Ju, J., Huang, A. C., Li, S., Ko, H., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00946-w · Cited by 29
Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies
Solassol, J., Vendrell, J. A., Senal, R., Audran, P., Leenhardt, F., & Quantin, X. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.003 · Cited by 27
Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives
Zhang, Y., Zhou, Q. H., & Wu, Y.-L. L. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.044 · Cited by 27
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
Yu, D., Zhao, W., Vallega, K. A., & Sun, S. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s293902 · Cited by 26
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
Lee, K., Kim, D., Yoon, S., Lee, K. H., & Kim, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.052 · Cited by 25
EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature
Batra, U., Sharma, M., Amrith, B. P., Mehta, A., & Jain, P. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.016 · Cited by 25
Novel molecular targets for the treatment of lung cancer
Rosell, R., Karachaliou, N., & Arrieta, O. G. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000590 · Cited by 24
CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib
Kato, R., Hayashi, H., Sakai, K., Suzuki, S., Haratani, K., Takahama, T., Tanizaki, J., Nonagase, Y., Tanaka, K., Yoshida, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01947-3 · Cited by 24
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
Lee, J., Chen, H., Hsu, F., Chen, J., Liao, W., Shih, J., Yu, C., Chen, K., Tsai, T.-H., & Yang, J. C. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0152 · Cited by 24
Self-citation
Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis
Wang, C., Zhao, K., Hu, S., Li, M., & Song, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.600844 · Cited by 23
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
Lin, Y., Tsai, T.-H., Wu, S., Liu, Y., Yu, C., & Shih, J. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.022 · Cited by 23
Self-citation
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Beau‐Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J., Bringuier, P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.013 · Cited by 21
Targeted therapies in non-small cell lung cancer: present and future
McLaughlin, J., Berkman, J. D., & Nana-Sinkam, P. S. (2023) · Faculty Reviews · doi:10.12703/r/12-22 · Cited by 22
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
Tan, L., Brown, C. S. B., Mersiades, A. J., Lee, C. K., John, T., Kao, S., Newnham, G. M., O'Byrne, K. J., Parakh, S., Bray, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46008-1 · Cited by 18
Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series
Jacobs, M. T., Mohindra, N. A., Shantzer, L., Chen, I. L., Phull, H. S., Mitchell, W., Raymond, V. M., Banks, K. C., Nagy, R. J., Lanman, R. B., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00318 · Cited by 18
Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Chen, H., Liu, M., Dai, Z., Li, S., Luo, Y., Wang, Y., Su, W., Cai, W., Yang, D., Huang, J., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-679 · Cited by 18
The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment
Ma, S., Shi, M., Chen, X., Wang, Y., Yang, Z., Lizaso, A., Li, M., Li, H., Zhang, L., Mao, X., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-371 · Cited by 17
EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
Zheng, Q., Huang, Y., Zhao, H., Yang, Y., Hong, S., Hou, X., Zhao, Y., Ma, Y., Zhou, T., Zhang, Y., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.35 · Cited by 17
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
Zhu, J., Yang, Q., & Xu, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091500 · Cited by 17
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
Vendrell, J. A., Quantin, X., Aussel, A., Solassol, I., Serre, I., & Solassol, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-679 · Cited by 16
Osimertinib plus Selumetinib in EGFR -Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Yang, J. C., Ohe, Y., Chiu, C., Ou, X., Cantarini, M., Janne, P. A., Hartmaier, R. J., & Ahn, M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4329 · Cited by 16
Self-citation
A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance
Qu, F., Zhou, Y., & Yu, W. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001242 · Cited by 16
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
Osoegawa, A., Yamaguchi, M., Nakamura, T., Morinaga, R., Tanaka, K., Kashiwabara, K., Miura, T., Suetsugu, T., Harada, T., Asoh, T., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100191 · Cited by 15
The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases
Hu, X., Liu, X., Khatri, U., & Wu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100958 · Cited by 15
Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
Tan, A. C., Teh, Y. L., Lai, G. G. Y., & Tan, D. S.-W. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1604228 · Cited by 15
The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
Zhao, Z., Li, L., Wang, Z., Duan, J., Bai, H., & Wang, J. (2020) · Journal of Cancer · doi:10.7150/jca.38411 · Cited by 14
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Li, Y., Zeng, H., Chen, Q., Tan, S., Huang, Q., Pu, X., Li, W., Planchard, D., & Tian, P. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103935 · Cited by 12
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Kuo, C. S., Huang, C.-H., Liu, C., Pavlidis, S. P., Ko, H., Chung, F., Lin, T., Wang, C., Guo, Y., & Yang, C. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00657-1 · Cited by 12
Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
Ishii, H., Azuma, K., Sakai, K., Naito, Y., Matsuo, N., Tokito, T., Yamada, K., Hoshino, T., & Nishio, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-57624-4 · Cited by 12
Next‐generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non‐small cell lung cancer
Zhang, Y., Xiong, L., Xie, F., Zheng, X., Li, Y., Zhu, L., & Sun, J. (2021) · Cancer Medicine · doi:10.1002/cam4.3948 · Cited by 12
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
Uehara, Y., Takeyasu, Y., Yoshida, T., Tateishi, A., Torasawa, M., Hosomi, Y., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100058 · Cited by 12
Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
Ariyasu, R., Uchibori, K., Sasaki, T., Tsukahara, M., Kiyotani, K., Yoshida, R., Ono, Y., Kitazono, S., Ninomiya, H., Ishikawa, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.14879 · Cited by 12
Cost‑effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor‑mutated non‑small‑cell lung cancer
Li, W., Qian, L., Li, W., Chen, X., He, H., Tian, H., Zhao, Y., Wang, X., & Cui, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9774 · Cited by 11
Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
Xiu, W., Zhang, Q., Yu, M., Huang, Y. C., & Huang, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.630256 · Cited by 11
Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer
Chang, L., Chiu, H., Ho, B., Chen, M., Hsu, Y.-C., Chiu, W.-T., Su, K., Shun, C., Liang, J., Yu, S., et al. (2020) · Cancers · doi:10.3390/cancers12061527 · Cited by 10
Self-citation
Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
Huang, M.-H., Lee, J., Hung, P.-S., & Yang, J. C. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100405 · Cited by 10
Self-citation
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
Luo, Y., Liang, K., Huang, H.-C., Shen, C., Chiang, C., Wang, M., Chiou, S., & Chen, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137037 · Cited by 10
The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer
Liam, C. K. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.45 · Cited by 10
Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Hsu, C., Yang, A. Y.-P., Chen, J.-Y., Tsai, H.-H., Lin, S.-H., Tai, P.-C., Huang, M.-H., Hsu, W.-H., Lin, A. M.-Y., & Yang, J. C. (2021) · Cancers · doi:10.3390/cancers13020272 · Cited by 10
Self-citation
Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review
Song, C., & Yang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834585 · Cited by 9
Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
Morán, T., Felip, E., Bosch‐Barrera, J., de Aguirre, I., Ramírez, J. L., Mesía, C., Carcereny, E., Roa, D., Sais, È., García, Y. G., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25478 · Cited by 9

Authors: Lin, C.-C., Shih, J.-Y., Yu, C.-J., Ho, C.-C., Liao, W.-Y., Lee, J.-H., Tsai, T.-H., Su, K.-Y., Hsieh, M.-S., Chang, Y.-L., Bai, Y.-Y., Huang, D. D.-R., Thress, K. S., & Yang, J. C.-H.
Affiliations: National Taiwan University Hospital (TW)
National Taiwan University (TW)
AstraZeneca (United States) (US)
Corresponding author: Yang, James Chih-Hsin
ORCID: Lin, Chia-Chi
Shih, Jin-Yuan
Yu, Chong-Jen
Ho, Chao-Chi
Liao, Wei-Yu
Tsai, Tzu-Hsiu
Su, Kang-Yi
Hsieh, Min-Shu
Chang, Yih-Leong
Huang, Derek De-Rui
Yang, James Chih-Hsin
Venue: The Lancet Respiratory Medicine
Publisher: Elsevier BV
Published: 2018-02
Volume: 6
Issue: 2
Pages: 107-116
ISSN: 2213-2600 (ISSN-L)
DOI: 10.1016/s2213-2600(17)30480-0
OpenAlex: W2772237551
Cited by: 145
References: 23
Citations by year: 2026: 3 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 15 · 2021: 29 · 2020: 20 · 2019: 24 · 2018: 16
FWCI: 13.80
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Respiratory Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: non-small cell lung cancer, osimertinib, acquired resistance, EGFR tyrosine kinase inhibitors, EGFR activating mutations, plasma biomarkers, resistance mechanisms, progression-free survival, overall survival, post-progression survival, third-generation EGFR-TKI
MeSH terms: Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Pyrimidines, Retrospective Studies, Genomics, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks